<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02470546</url>
  </required_header>
  <id_info>
    <org_study_id>EME-2015</org_study_id>
    <nct_id>NCT02470546</nct_id>
  </id_info>
  <brief_title>Metformin Experience on Minimal Hepatic Encephalopathy</brief_title>
  <acronym>EME</acronym>
  <official_title>Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary aim:

      -To assess the effect of metformin use on the treatment of minimal hepatic encephalopathy in
      patients with liver cirrhosis.

      Secondary aim:

      -To evaluate if metformin is a safety drug in patients showing liver cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, 30 patients will be included divided in two arms. Investigators and patients
      will not know the treatment used (double blind).

      Arm 1: Metformin 1000mg twice a day (2000 mg/day), during 12 weeks. Arm 2: Placebo 1000mg
      twice a day (2000mg/day), during 12 weeks.

      At the end of the study, patients will be followed-up 8 weeks more to control the appearance
      of adverse effects.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with Minimal hepatic encephalopathy</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measurement of the results of critical flicker frequency after 12 weeks of metformin treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Minimal hepatic encephalopathy</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measurement of the results of PHES after 12 weeks of metformin treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receiving placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 1000mg twice a day</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Drug 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1000mg twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Drug 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with &gt; 18 years old

          -  Patients with the results of all the factors evaluable at the time of inclusion

          -  Patients who have accepted their participation in the study through informed consent

          -  Patients showing liver cirrhosis by ultrasound, transient elastography or liver biopsy

          -  Patients showing minimal hepatic encephalopathy (PHES &lt; 4 or Critical Flicker
             Frequency &lt; 39 Hz)

        Exclusion Criteria:

          -  Patients with any contraindications to the drugs used

          -  Patients showing type 1 diabetes mellitus

          -  Patients showing type 2 diabetes mellitus and previous or current use of exogenous
             insulin, metformin or other oral antidiabetic drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Romero-Gomez, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Valme University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuel Romero-Gomez, PhD, MD</last_name>
    <email>mromerogomez@us.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fundación Pública Andaluza para la Gestión de la investigación en salud de Sevilla (FISEVI)</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Romero-Gomez, PhD, MD</last_name>
      <email>mromerogomez@us.es</email>
    </contact>
    <investigator>
      <last_name>Javier Ampuero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2014</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <last_update_submitted>June 9, 2015</last_update_submitted>
  <last_update_submitted_qc>June 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic encephalopathy</keyword>
  <keyword>Metformin</keyword>
  <keyword>Liver cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

